Course Description
Large language models (LLMs) are becoming increasingly integrated into everyday life, raising new questions about their potential impact on individuals experiencing psychosis. This session will examine reported cases in which interactions with artificial intelligence (AI) have been associated with the onset or worsening of psychotic symptoms, including cases involving serious harm, and explore the similarities observed in AI-generated reinforcement of delusional beliefs. Participants will review the current evidence, discuss the legal and ethical implications of these emerging reports, and consider how LLM guardrails may help mitigate potential risks. Join this timely session to better understand the evolving intersection of AI, psychosis, and psychiatric pharmacy practice, and to prepare for the conversations with patients who may be using these rapidly advancing technologies.
Learning Objectives
- Identify symptoms of artificial intelligence (AI) psychosis including similarities in delusional content across cases.
- Explain how large language models (LLMs) serve to amplify delusional content during psychosis.
- Describe legal cases that involved AI psychosis and resulted in suicide and/or homicide.
- Discuss considerations for improving LLM "guardrails" to mitigate the risk of AI psychosis.
Target Audience
If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.
Faculty
View biographical information
Kristin Waters, PharmD, BCPS, BCPP
Associate Clinical Professor
University of Connecticut School of Pharmacy and Pharmaceutical Sciences
Storrs, CT
Kristin Waters, PharmD, BCPS, BCPP, is an Associate Clinical Professor at the University of Connecticut School of Pharmacy and Pharmaceutical Sciences in Storrs, CT. She precepts pharmacy students and pharmacy residents at Yale New Haven Hospital. Her clinical time is spent mostly on the inpatient general adult and geriatric psychiatry units. She attended the Philadelphia College of Pharmacy and completed her PGY-1 pharmacy practice residency at St. Joseph’s Hospital in Syracuse, NY. She then completed her PGY-2 residency in psychiatric pharmacy at Yale New Haven Hospital.
Kristin is a member of the Board of Pharmacy Specialties Psychiatric Pharmacy Specialty Council, and an active contributor to the American Association of Psychiatric Pharmacists through leadership roles on the Commission on Innovation and Advancement, Outcomes Research Committee, and other task forces. She co-developed an 8-hour continuing education program that trains pharmacists to administer long-acting injectable (LAI) medications for psychiatric and substance use disorders.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
Activity Dates: 4/6/2027-4/6/2030
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-##-###-###-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
View AAPP's Disclaimer and Disclosure Declarations
AAPP Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Unlabeled Use Disclosure: Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. The faculty, planners, and American Association of Psychiatric Pharmacists do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
View AAPP's Copyright Statement, Terms of Use, and Policies
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View AAPP's Privacy Policy. AAPP's Terms of Use and other policies on education programs, resources, toolkits, and other web based content/offerings are available here.
View AAPP's Fair Balance and Integrity Statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.